KR102576165B1 - 침윤성 뇌암 동물 모델 및 이의 제조방법 - Google Patents
침윤성 뇌암 동물 모델 및 이의 제조방법 Download PDFInfo
- Publication number
- KR102576165B1 KR102576165B1 KR1020210018188A KR20210018188A KR102576165B1 KR 102576165 B1 KR102576165 B1 KR 102576165B1 KR 1020210018188 A KR1020210018188 A KR 1020210018188A KR 20210018188 A KR20210018188 A KR 20210018188A KR 102576165 B1 KR102576165 B1 KR 102576165B1
- Authority
- KR
- South Korea
- Prior art keywords
- brain cancer
- cells
- invasive
- animal model
- invasion
- Prior art date
Links
- 208000003174 Brain Neoplasms Diseases 0.000 title claims abstract description 111
- 238000010171 animal model Methods 0.000 title claims abstract description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 230000009545 invasion Effects 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 25
- 208000005017 glioblastoma Diseases 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 11
- 206010027476 Metastases Diseases 0.000 claims abstract description 10
- 230000009401 metastasis Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 102
- 206010028980 Neoplasm Diseases 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 17
- 230000002861 ventricular Effects 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 9
- 230000004709 cell invasion Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000013513 substance screening Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 27
- 239000002609 medium Substances 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 18
- 239000003636 conditioned culture medium Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000032612 Glial tumor Diseases 0.000 description 8
- 206010018338 Glioma Diseases 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108091023037 Aptamer Proteins 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 101150074545 Zeb1 gene Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000009816 chondrogenic differentiation Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 230000009815 adipogenic differentiation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000009818 osteogenic differentiation Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101150090421 GO gene Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108050000637 N-cadherin Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000014564 chemokine production Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- -1 nucleoside triphosphates Chemical class 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210018188A KR102576165B1 (ko) | 2021-02-09 | 2021-02-09 | 침윤성 뇌암 동물 모델 및 이의 제조방법 |
PCT/KR2022/001962 WO2022173212A1 (fr) | 2021-02-09 | 2022-02-09 | Modèle animal de cancer invasif du cerveau et son procédé de production |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210018188A KR102576165B1 (ko) | 2021-02-09 | 2021-02-09 | 침윤성 뇌암 동물 모델 및 이의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220114774A KR20220114774A (ko) | 2022-08-17 |
KR102576165B1 true KR102576165B1 (ko) | 2023-09-07 |
Family
ID=82838417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210018188A KR102576165B1 (ko) | 2021-02-09 | 2021-02-09 | 침윤성 뇌암 동물 모델 및 이의 제조방법 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102576165B1 (fr) |
WO (1) | WO2022173212A1 (fr) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104582477B (zh) * | 2012-06-21 | 2018-09-21 | 社会福祉法人三星生命公益财团 | 制备患者特异性胶质母细胞瘤动物模型的方法及其用途 |
KR101613709B1 (ko) * | 2014-06-12 | 2016-04-20 | 연세대학교 산학협력단 | 뇌암의 침윤 및 이동 억제용 약제학적 조성물 |
KR102125084B1 (ko) * | 2018-04-18 | 2020-06-19 | 서울대학교산학협력단 | 신규한 교모세포종 환자 유래 이종 이식 모델 및 이의 용도 |
-
2021
- 2021-02-09 KR KR1020210018188A patent/KR102576165B1/ko active IP Right Grant
-
2022
- 2022-02-09 WO PCT/KR2022/001962 patent/WO2022173212A1/fr active Application Filing
Non-Patent Citations (6)
Title |
---|
Annals of Surgical Oncology, 2012, 19권, 페이지 S608-S619 |
Neuro-Oncology, 2015, 17권, 1호, 페이지 81-94 |
Neuro-Oncology, 2020, 22권, 10호, 페이지 1452-1462 |
Oncotarget. vol.9 no.37 pp.24766-24777 2018. |
강석구, 이공학개인기초연구지원사업 최종(결과)보고서(2017.11.18.)* |
강석구, 이공학개인기초연구지원사업 최종(결과)보고서(2020.05.23.)* |
Also Published As
Publication number | Publication date |
---|---|
WO2022173212A1 (fr) | 2022-08-18 |
KR20220114774A (ko) | 2022-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ren et al. | Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression | |
Nishikawa et al. | Significance of glioma stem‐like cells in the tumor periphery that express high levels of CD44 in tumor invasion, early progression, and poor prognosis in glioblastoma | |
EP2529223B1 (fr) | Biomarqueurs pour cellules tumorales en circulation | |
CN103907022A (zh) | 用于治疗和诊断结直肠癌的方法和组合物 | |
CN103890587A (zh) | 用于治疗和诊断癌症的方法和组合物 | |
CN104080924A (zh) | 用于治疗和诊断乳腺癌的方法和组合物 | |
Messai et al. | Cytokeratin 18 expression pattern correlates with renal cell carcinoma progression: relationship with Snail | |
Zhai et al. | Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma | |
CN108203732B (zh) | Trim24在胶质瘤诊断中的应用 | |
KR102216590B1 (ko) | 췌장 신경내분비종양의 진단을 위한 조성물 | |
US20180221479A1 (en) | Agents for use in the treatment of glioma | |
Park et al. | Integrin β1 regulates the perineural invasion and radioresistance of oral squamous carcinoma cells by modulating cancer cell stemness | |
US20120252748A1 (en) | Methods and compositions for determining the responsiveness of cancer therapeutics | |
Zhang et al. | MiR-15 suppressed the progression of bladder cancer by targeting BMI1 oncogene via PI3K/AKT signaling pathway. | |
KR102576165B1 (ko) | 침윤성 뇌암 동물 모델 및 이의 제조방법 | |
EP3460476B1 (fr) | Composition de biomarqueur comprenant lrp-1 en tant que principe actif pour le diagnostic du cancer résistant à l'irradiation ou la prédiction du pronostic d'une radiothérapie | |
KR101885982B1 (ko) | 구강암 예후측정용 마커로서의 nab2의 용도 | |
Ho et al. | Snail induces dormancy in disseminated luminal type A breast cancer through Src inhibition | |
KR101807356B1 (ko) | 뇌암 환자의 생존 기간 예측용 키트와 생존 기간 예측을 위한 정보 제공 방법 | |
US20220135979A1 (en) | Diagnosis and treatment of medulloblastoma | |
US20160274118A1 (en) | Biomarker of liver cancer and uses thereof | |
KR102178432B1 (ko) | 침윤성 뇌암의 진단용 조성물 | |
CN107385081B (zh) | 一种与肾癌相关的基因及其应用 | |
KR101926841B1 (ko) | Srf-yap 및 yap 시그니쳐를 이용한 줄기세포특성을 보이는 기저양 유방암 및 삼중 음성 유방암 진단 및 치료방법 | |
WO2018025869A1 (fr) | Biomarqueur pour prédiction de l'effet thérapeutique d'un inhibiteur de fstl1 chez un patient cancéreux |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |